News | April 19, 2021
Vaishali Pharma initiates 30 products registration
The company also plans to register the similar range of products in the neighbouring countries.
The company also plans to register the similar range of products in the neighbouring countries.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
The company received one observation in the Form-483
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The company received 1 (One) observation in the Form-483
Subscribe To Our Newsletter & Stay Updated
